Venlafaxine Hydrochloride Capsule, Extended Release
Product Images NDC 68071-4442

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Venlafaxine Hydrochloride (NDC 68071-4442). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

68071 4442 9

Label for venlafaxine hydrochloride 150 mg extended-release capsules by NuCare Pharmaceuticals, Inc. The label shows a package count of 90 capsules and includes NDC 68071-4442-9. It indicates prescription only and has warnings to keep out of reach of children and store at controlled temperatures 68-77°F. Manufacturer noted as Cadila Healthcare Ltd, India.*

FDA Label Image

Venlafaxine Hydrochloride Extended-release Capsules, Usp (Venlafaxineercaps Figure 01)

A pharmacokinetic chart showing the fold change and 90% confidence interval for venlafaxine in the presence of various interacting drugs, including ethanol, diazepam, cimetidine, ketoconazole, indinavir, metoprolol, imipramine, and lithium. The X-axis represents change relative to the reference value, displaying Cmax and AUC values with corresponding clinical recommendations.*

FDA Label Image

Venlafaxine Hydrochloride Extended-release Capsules, Usp (Venlafaxineercaps Figure 02)

A chart showing drug interaction data between venlafaxine hydrochloride and multiple interacting drugs, depicting analyte, PKFold change with 90% confidence intervals, and clinical recommendations. The horizontal axis shows change relative to the reference value, with various drugs such as ethanol, diazepam, alprazolam, indinavir, metoprolol, risperidone, imipramine, haloperidol, caffeine, tolbutamide, and lithium listed, alongside recommendations like dose adjustments or cautions.*

FDA Label Image

Venlafaxine Hydrochloride Extended-release Capsules, Usp (Venlafaxineercaps Figure 03)

A dot plot chart presenting the pharmacokinetic (PK) fold change with 90% confidence intervals for venlafaxine and its metabolite ODV across various special populations. The chart compares Cmax and AUC changes relative to a reference value for groups including hepatic and renal impairments, CYP2D6 polymorphism, age over 60 years, and gender. Recommendations for dose adjustments are listed, such as reducing dose in hepatic or renal impairment and no adjustment needed for CYP2D6 polymorphism or older age.*

FDA Label Image

Venlafaxine Hydrochloride Extended-release Capsules, Usp (Venlafaxineercaps Figure 04)

Chemical structure of venlafaxine hydrochloride, showing its molecular arrangement including a cyclohexanol ring, dimethylaminoethyl side chain, and methoxyphenyl group, labeled with the compound name below the diagram.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.